Jump to content

Asfotase alfa

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Mahmoudalrawi (talk | contribs) at 13:17, 30 April 2016. The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Asfotase alfa
Clinical data
Trade namesStrensiq
Routes of
administration		Subcutaneous injection
Legal status
Legal status

Asfotase alfa is a drug used in the Treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia[1][2]

Asfotase alfa is manufactured by Alexion Pharmaceuticals and It was granted breakthrough therapy designation by FDA in 2015.

References

  1. ^ CDER Breakthrough Therapy Designation Approvals
  2. ^ FDA approves new treatment for rare metabolic disorder
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Asfotase_alfa&oldid=717910969"